Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
graft-versus-host disease
Fierce Pharma
Sanofi inks $1.5B deal for Sino Biopharm's novel asset
Sanofi is committing $1.53 billion to license a first-in-class JAK/ROCK inhibitor from Sino Biopharm with eyes on both hematology and immunology.
Angus Liu
Mar 4, 2026 3:00am
Equillium misses primary, key secondaries, plans approval filing
Mar 27, 2025 9:52am
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing
Jan 9, 2025 5:18am
Viral protein suppresses graft vs. host disease in mice
Jul 19, 2024 5:30am
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
Apr 15, 2024 7:05am
